| |
CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS
IS NONINFERIOR TO MONTHLY: ATLAS-2M STUDY
|
| |
| |
ACTHIV - American Conference for the Treatment of HIV Aug 20-22 2020 virtual
Reported by Jules Levin
Edgar T. Overton,1 Gary Richmond,2 Giuliano Rizzardini,3 Hans Jaeger,4 Catherine Orrell,5 Firaya Nagimova,6 Fritz Bredeek,7 Miguel García del Toro,8 Paul D. Benn,9
Yuanyuan Wang,10 Krischan J. Hudson,11 David A. Margolis,11 Kimberly Smith,11 Peter E. Williams,12 William Spreen,11 Paula Teichner11
1University of Alabama at Birmingham, Birmingham, AL, USA; 2Broward General Health Medical Center, Fort Lauderdale, FL, USA; 3Fatebenefratelli Sacco Hospital, Milan, Italy; 4HIV Research and Clinical Care Center, Munich, Germany; 5Desmond Tutu HIV Foundation, University of Cape Town Medical School, Cape Town, South Africa; 6Republic Center for the Prevention and Control of AIDS and Infectious Diseases, Russia; 7Metropolis Medical, San Francisco, CA, USA; 8General Hospital of Valencia, Valencia, Spain; 9ViiV Healthcare, Brentford, UK; 10GlaxoSmithKline, Collegeville, PA, USA; 11ViiV Healthcare, Research Triangle Park, NC, USA; 12Janssen Research & Development, Beerse, Belgium
|
|
| |
| |
|
|
|
